The collaboration will use ImmunoGen’s linker-payload technology which is directed to new targets that are identified by OBT through its OGAP discovery platform. The two companies will jointly
The post ImmunoGen, OBT partner to develop new antibody-drug conjugates for cancers appeared first on Pharmaceutical Business review.